Funded by the Knut & Alice Wallenberg foundation, the Human Protein Atlas was initiated in 2003 by Swedish researchers to map the entire human proteome. Based on strong research demand, Atlas Antibodies was formed 2006 to commercialize the over 20,000 antibodies developed within the project. Today, the product suite encompasses polyclonal and monoclonal antibodies and mass spec standards.
2021, the company acquired Swiss-based evitria, a high-quality customized recombinant antibody provider, and HistoCyte Laboratories, a global leader in cell line controls. These acquisitions brought together a leading provider of highly validated research antibodies with a front-runner in the field of customized recombinant antibody expression and a provider of innovative cell line materials. Together, the joint entity serves a broad customer group, from research and academic labs, to hospital labs, small biotech, and larger pharmaceuticals.
During the past ten years, the joint company has experienced double digit annual growth rates. The company’s products and services are available across the globe, with current sales evenly split between North America and Europe, with a growing presence in APAC.
Recent highlights
August 2021; acquired evitria, a quality-leader within customized recombinant antibodies
February 2021; completed acquisition of HistoCyte Laboratories, a UK-based provider of innovative cell line controls for use in histopathology
Click here for Atlas Antibodies’ website
Atlas Antibodies - Key facts
|
SEK m. |
2023 |
2022 |
|
Sales |
371 |
398 |
|
EBITDA (%) |
40 |
47 |
|
Number of employees |
120 |
130 |
|
Patricia Industries ownership (capital/votes): 88/88 | Initial investment year: 2006 (majority owner 2018) |